Evidence map›Paper›PMID 38995784›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Mayo Normative Studies: Amyloid and Neurodegeneration Negative Normative Data for the Auditory Verbal Learning Test and Sex-Specific Sensitivity to Mild Cognitive Impairment/Dementia.

Nikki H Stricker, Teresa J Christianson, Shehroo B Pudumjee, Angelina J Polsinelli, Emily S Lundt, Ryan D Frank, Walter K Kremers, Mary M Machulda, Julie A Fields, Clifford R Jack and 5 more

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Development of amyloid-negative neuropsychological norms using GAMLSS.Alzheimer's & dementia (Amsterdam, Netherlands)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nikki H StrickerDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Teresa J ChristiansonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Shehroo B PudumjeeCleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Angelina J PolsinelliDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
Emily S LundtDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Ryan D FrankDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Walter K KremersDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Rochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Validation of the Mayo Test Drive Screening Battery Composite and Stricker Learning Span for Early Detection and Monitoring of Cognitive Decline in Preclinical and Prodromal Alzheimer’s DiseaseR01AG081955 · NIA · MAYO CLINIC ROCHESTER · PI Nikki H Stricker · 2024 to 2026
$4.4M
Reproductive risk factors for Alzheimer's disease dementia and pathologyRF1AG055151 · NIA · MAYO CLINIC ROCHESTER · PI MIELKE, MICHELLE M, ROCCA, WALTER A · 2017 to 2017
$4.0M
Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
Stricker Learning Span: A Computer Adaptive Word List Memory Test Optimized for Remote AssessmentR21AG073967 · NIA · MAYO CLINIC ROCHESTER · PI STRICKER, NIKKI H · 2021 to 2021
$437k
NIA NIH HHS R01 AG034676NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG081955NIA NIH HHS R21 AG073967NIA NIH HHS R33 AG058738NIA NIH HHS RF1 AG055151NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

Background: Conventional normative samples include individuals with undetected Alzheimer's disease neuropathology, lowering test sensitivity for cognitive impairment. Objective: We developed Mayo Normative Studies (MNS) norms limited to individuals without elevated amyloid or neurodegeneration (A-N-) for Rey's Auditory Verbal Learning Test (AVLT). We compared these MNS A-N- norms in female, male, and total samples to conventional MNS norms with varying levels of demographic adjustments. Methods: The A-N- sample included 1,059 Mayo Clinic Study of Aging cognitively unimpaired (CU) participants living in Olmsted County, MN, who are predominantly non-Hispanic White. Using a regression-based approach correcting for age, sex, and education, we derived fully-adjusted T-score formulas for AVLT variables. We validated these A-N- norms in two independent samples of CU (n = 261) and mild cognitive impairment (MCI)/dementia participants (n = 392) > 55 years of age. Results: Variability associated with age decreased by almost half in the A-N- norm sample relative to the conventional norm sample. Fully-adjusted MNS A-N- norms showed approximately 7- 9% higher sensitivity to MCI/dementia compared to fully-adjusted MNS conventional norms for trials 1- 5 total and sum of trials. Among women, sensitivity to MCI/dementia increased with each normative data refinement. In contrast, age-adjusted conventional MNS norms showed greatest sensitivity to MCI/dementia in men. Conclusions: A-N- norms show some benefits over conventional normative approaches to MCI/dementia sensitivity, especially for women. We recommend using these MNS A-N- norms alongside MNS conventional norms. Future work is needed to determine if normative samples that are not well characterized clinically show greater benefit from biomarker-refined approaches.

Indexed as

Cognitive DysfunctionVerbal LearningAgedAged, 80 and overDementiaFemaleHumansMaleMiddle AgedNeuropsychological TestsReference ValuesSex FactorsAlzheimer’s diseasebiomarker normscognitive agingdementiamemorymild cognitive impairmentneuropsychologyRey’s Auditory Verbal Learning Testrobust normssensitivity and specificity

Identifiers

PMID38995784
PMCPMC11307010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.